Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (49)
- Life Sciences (20)
- Medical Sciences (20)
- Oncology (20)
- Hematology (18)
-
- Internal Medicine (16)
- Bioinformatics (15)
- Biomedical Informatics (14)
- Genetic Phenomena (14)
- Medical Genetics (14)
- Neoplasms (13)
- Pathological Conditions, Signs and Symptoms (13)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (12)
- Immune System Diseases (7)
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)
- Public Health (6)
- Therapeutics (5)
- Bacterial Infections and Mycoses (4)
- Chemicals and Drugs (4)
- Investigative Techniques (4)
- Virus Diseases (4)
- Cardiovascular Diseases (3)
- Digestive System Diseases (3)
- Pediatrics (3)
- Amino Acids, Peptides, and Proteins (2)
- Anatomy (2)
- Biochemistry, Biophysics, and Structural Biology (2)
- Institution
- Keyword
-
- Humans (13)
- Female (11)
- Leukemia (11)
- Male (11)
- Adult (10)
-
- Aged (9)
- Middle Aged (8)
- Acute (5)
- Leukemia, Myeloid, Acute (5)
- Sulfonamides (5)
- Young Adult (5)
- Aged, 80 and over (4)
- Bridged Bicyclo Compounds (4)
- Bridged Bicyclo Compounds, Heterocyclic (4)
- Heterocyclic (4)
- Myeloid (4)
- 80 and over (3)
- Adolescent (3)
- Anemia (3)
- Chronic (3)
- Lymphoma (3)
- Middle aged (3)
- Pilot Projects (3)
- Antineoplastic Combined Chemotherapy Protocols (2)
- Apoptosis (2)
- B-Cell (2)
- Drug Resistance (2)
- Drug Resistance, Neoplasm (2)
- Escherichia coli (2)
- Feasibility Studies (2)
- Publication
-
- Faculty, Staff and Student Publications (16)
- Rowan-Virtua Research Day (6)
- Gulf Coast Division GME Research Day 2025 (5)
- School of Medicine Faculty Publications (4)
- Central & West Texas and San Antonio GME Research Day 2025 (2)
-
- Department of Medicine Faculty Publications (2)
- South Atlantic Division GME Research Day 2025 (2)
- Cardeza Foundation for Hematologic Research (1)
- Chemistry & Biochemistry Faculty Publications (1)
- Department of Anesthesiology Faculty Papers (1)
- Department of Dermatology and Cutaneous Biology Faculty Papers (1)
- Department of Medical Oncology Faculty Papers (1)
- Department of Medicine Faculty Papers (1)
- Department of Orthopaedic Surgery Faculty Papers (1)
- Department of Pathology, Anatomy, and Cell Biology Faculty Papers (1)
- Department of Physical Therapy Faculty Papers (1)
- Division of Nephrology Faculty Papers (1)
- East Florida Division GME Research Day 2025 (1)
- Electronic Theses and Dissertations (1)
- Global Health Articles (1)
- HCA Healthcare Journal of Medicine (1)
- Jurnal Penyakit Dalam Indonesia (1)
- Marshall Journal of Medicine (1)
- North Florida Division GME Research Day 2025 (1)
- North Texas Research Forum 2025 (1)
- Oncology Rehabilitation in Practice (1)
- Pharmacy Faculty Articles and Research (1)
- Publications and Research (1)
- Research Colloquium (1)
- Research Data (1)
- Publication Type
Articles 61 - 65 of 65
Full-Text Articles in Hemic and Lymphatic Diseases
Deep Dive Into Targeted Therapies: Understanding Idh1-Mutant Aml Treatments [Podcast], Amer M Zeidan, Courtney Dinardo
Deep Dive Into Targeted Therapies: Understanding Idh1-Mutant Aml Treatments [Podcast], Amer M Zeidan, Courtney Dinardo
Faculty, Staff and Student Publications
This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies. Through discussion of key findings from pivotal clinical trial studies, including data supporting the use of these agents in both newly diagnosed and relapsed or refractory (R/R) settings, the episode highlights significant outcomes such as increased overall response and prolonged duration of remission in patients treated with IDH1 inhibitors. The analysis …
The Impact Of Post-Remission Granulocyte Colony-Stimulating Factor Use In The Phase 3 Studies Of Venetoclax Combination Treatments In Patients With Newly Diagnosed Acute Myeloid Leukemia, Courtney D Dinardo, Keith W Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev, Árpád Illés, Inho Kim, Vladimir Ivanov, Grace Ku, Catherine L Miller, Meng Zhang, Fernando Tatsch, Jalaja Potluri, Xenia Schmidt, Christian Récher
The Impact Of Post-Remission Granulocyte Colony-Stimulating Factor Use In The Phase 3 Studies Of Venetoclax Combination Treatments In Patients With Newly Diagnosed Acute Myeloid Leukemia, Courtney D Dinardo, Keith W Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev, Árpád Illés, Inho Kim, Vladimir Ivanov, Grace Ku, Catherine L Miller, Meng Zhang, Fernando Tatsch, Jalaja Potluri, Xenia Schmidt, Christian Récher
Faculty, Staff and Student Publications
No abstract provided.
Lp-118 Is A Novel B-Cell Lymphoma 2 / Extra-Large Inhibitor That Demonstrates Efficacy In Models Of Venetoclaxresistant Chronic Lymphocytic Leukemia, Janani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai, Shrilekha Misra, Charmelle D Williams, John Sanchez, Andrew Mitchell, Suresh Satpati, Elizabeth Perry, Tierney Kaufman, Chaomei Liu, Arletta Lozanski, Gerard Lozanski, Kerrya Rogers, Adam S Kittai, Seema A Bhat, Mary C Collins, Matthew S Davids, Nitin Jain, William G Wierda, Rosa Lapalombella, John C Byrd, Fenlai Tan, Yi Chen, Yu Chen, Yue Shen, Stephen P Anthony, Jennifer A Woyach, Deepa Sampath
Lp-118 Is A Novel B-Cell Lymphoma 2 / Extra-Large Inhibitor That Demonstrates Efficacy In Models Of Venetoclaxresistant Chronic Lymphocytic Leukemia, Janani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai, Shrilekha Misra, Charmelle D Williams, John Sanchez, Andrew Mitchell, Suresh Satpati, Elizabeth Perry, Tierney Kaufman, Chaomei Liu, Arletta Lozanski, Gerard Lozanski, Kerrya Rogers, Adam S Kittai, Seema A Bhat, Mary C Collins, Matthew S Davids, Nitin Jain, William G Wierda, Rosa Lapalombella, John C Byrd, Fenlai Tan, Yi Chen, Yu Chen, Yue Shen, Stephen P Anthony, Jennifer A Woyach, Deepa Sampath
Faculty, Staff and Student Publications
Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity to BCL2 targeting, but durability of response remains a concern. We hypothesize that targeting both BCL2 and B-cell lymphoma-extra large (BCLXL) will be a successful strategy to treat CLL, including for patients who relapse on venetoclax. To test this hypothesis, we conducted a pre-clinical investigation of LP-118, a highly potent inhibitor of BCL2 with moderate BCLXL inhibition to minimize platelet toxicity. This study demonstrated that LP-118 induces efficient BAK activation, cytochrome C release, and apoptosis …
Management Of Hemolytic Transfusion Reactions In A Patient With Chronic Myelomonocytic Leukemia And Rare Antibodies: A Case Report, Grace S Park, Himachandana Atluri, Courtney D Dinardo, Bryan Guillroy, Jean Horak, Effrosyni Apostolidou, Maryam Buni, Guillermo Montalban Bravo, Naveen Pemmaraju
Management Of Hemolytic Transfusion Reactions In A Patient With Chronic Myelomonocytic Leukemia And Rare Antibodies: A Case Report, Grace S Park, Himachandana Atluri, Courtney D Dinardo, Bryan Guillroy, Jean Horak, Effrosyni Apostolidou, Maryam Buni, Guillermo Montalban Bravo, Naveen Pemmaraju
Faculty, Staff and Student Publications
Delayed hemolytic transfusion reaction (DHTR) poses a significant challenge in patients receiving blood transfusions. This case report highlights the complexities of managing DHTR in a newly diagnosed chronic myelomonocytic leukemia (CMML) patient with clinically significant JKa and little c antibodies during induction chemotherapy. A 46-year-old woman with CMML-2 who presented for induction chemotherapy was found to have hemolytic anemia. Due to presence of JKa and little c antibodies, she required intensive monitoring and supportive care measures. The coexistence of JKa and little c antibodies complicates transfusion management and chemotherapy tolerance in CMML patients.
High-Grade B-Cell Lymphoma Not Otherwise Specified, With Diffuse Large B-Cell Lymphoma Gene Expression Signatures: Genomic Analysis And Potential Therapeutics, Waseem Lone, Alyssa Bouska, Tyler A Herek, Catalina Amador, Joo Song, Alexander M Xu, Dylan Jochum, Issa Ismail Issa, Dennis D Weisenburger, Xuan Zhang, Sharath Kumar Bhagavathi, Tayla B Heavican-Foral, Sunandini Sharma, Ab Rauf Shah, Abdul Rouf Mir, Aisha Ahmad Alkhinji, Dalia El-Gamal, Bhavana J Dave, Keenan Hartert, Jiayu Yu, Mallick Saumyaranjan, Timothy C Greiner, Julie Vose, Timothy W Mckeithan, Kai Fu, Michael Green, Chengfeng Bi, Akil Merchant, Wing C Chan, Javeed Iqbal
High-Grade B-Cell Lymphoma Not Otherwise Specified, With Diffuse Large B-Cell Lymphoma Gene Expression Signatures: Genomic Analysis And Potential Therapeutics, Waseem Lone, Alyssa Bouska, Tyler A Herek, Catalina Amador, Joo Song, Alexander M Xu, Dylan Jochum, Issa Ismail Issa, Dennis D Weisenburger, Xuan Zhang, Sharath Kumar Bhagavathi, Tayla B Heavican-Foral, Sunandini Sharma, Ab Rauf Shah, Abdul Rouf Mir, Aisha Ahmad Alkhinji, Dalia El-Gamal, Bhavana J Dave, Keenan Hartert, Jiayu Yu, Mallick Saumyaranjan, Timothy C Greiner, Julie Vose, Timothy W Mckeithan, Kai Fu, Michael Green, Chengfeng Bi, Akil Merchant, Wing C Chan, Javeed Iqbal
Faculty, Staff and Student Publications
High-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and NOS, that demonstrate gene expression profiling (GEP), and genetic signatures similar to BL. Herein, we characterize distinct HGBCL, NOS, cohort (n = 55) in adults (n = 45) and in children (n = 10), and compared the GEP, genomic DNA copy number (CN), and mutational spectrum with de novo DLBCL (n = 85) and BL (n = 52). …